Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vigil Neuroscience
Biotech
FDA greenlights Vigil's Alzheimer's trial—with a partial hold
Vigil has been granted clearance from the FDA to launch an Alzheimer’s trial, but that approval comes with strings attached: a partial clinical hold.
Gabrielle Masson
Sep 11, 2023 12:00pm
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Roche's executive dominoes continue to tip—Chutes & Ladders
Dec 16, 2022 9:30am
Vigil bags $90M to take ex-Amgen CNS assets into the clinic
Aug 18, 2021 7:00am
Vigil targets 'sentinel cells' to fight neurodegeneneration
Dec 8, 2020 8:00am
